1342 Novel Oncomagnetic Treatment of GBM and DIPG-Bench to Bedside Studies With Updated Rx of 11 patients

INTRODUCTION: We have developed a novel technololgy to treat GBM and DIPG utilizing oscillating magnetic fields (OMF) to kill tumor cells. The mechanism of action is to increase reactive oxygen species in the mitochondria to toxic levels. Normal brain cells have low ROS levels and high antixoxidant defenses and are not affected by this therapy. This presentation provides updates regarding our work METHODS: We delineated mechanisms of actions in cell culture studes assessing for reactive oxygen species and caspase 3 expression. Clonogenic assays, cell survival studies, flow cytometry, and RNA sequencing were utilized. Efficacy was assessed using syngeneic and PDX mouse models and expanded access treatment in 9 GBM and two DIPG patients. RESULTS: Cell culture studies documented elevation of ROS leading to apoptotic cell death. Optimal oscillating frequencies and on off parameters were determined. Six hours per day of treatment were sufficienct for optimal results. Effects were demonstrated in both syngeneic and PDX mouse glioma using 7T MRI scans.9 endstage GBM patients and two DIPG patients were treated using a removable helmet, six hours a day. No head shave or electrodes were required. Patients received treatment in two hour blocks, thrice daily. Dramatic reduction in contrast enhancement and improvement in OS were seen in 7/9 GBM patient & 1 DIPG patient. No adverse events occurred. CONCLUSIONS: OMF is a pwerful and disruptive technology for treatment of GBM. IDE studies in the US and clinical trials in Europe are underway to further study this potentially powerful technique, which may reduce the need for Chemoradiation and resulting toxicity.